The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

X. G. L. V. Pouwels; S. M. E. Geurts; B. L. T. Ramaekers; F. Erdkamp; B. E. P. J. Vriens; K. N. A. Aaldering; A. J. van de Wouw; M. W. Dercksen; T. J. Smilde; N. A. J. B. Peters; J. M. van Riel; M. J. Pepels; J. Heijnen-Mommers; M. A. Joore; V. C. G. Tjan-Heijnen; M. de Boer

doi:10.1080/0284186X.2019.1670356

The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

X. G. L. V. Pouwels, S. M. E. Geurts, B. L. T. Ramaekers, F. Erdkamp, B. E. P. J. Vriens, K. N. A. Aaldering, A. J. van de Wouw, M. W. Dercksen, T. J. Smilde, N. A. J. B. Peters, J. M. van Riel, M. J. Pepels, J. Heijnen-Mommers, M. A. Joore, V. C. G. Tjan-Heijnen, M. de Boer^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Web of Science)

Abstract

Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013-2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7-5.5) in the eribulin group and 3.2 months (95% CI: 2.0-4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49-1.38). Median OS was 5.9 months (95% CI: 4.6-11.0) and 5.2 months (95% CI: 4.6-9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38-1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.

Original language	English
Pages (from-to)	82-89
Number of pages	8
Journal	Acta Oncologica
Volume	59
Issue number	1
DOIs	https://doi.org/10.1080/0284186X.2019.1670356
Publication status	Published - 2 Jan 2020

Keywords

Eribulin
breast neoplasms
matching
genetic matching
relative effectiveness
EXPANDED ACCESS PROGRAM
EFFICACY
MESYLATE
SAFETY
CAPECITABINE
MONOTHERAPY
MULTICENTER
TOXICITY

Access to Document

10.1080/0284186X.2019.1670356Licence: CC BY-NC-ND

Cite this

Pouwels, X. G. L. V., Geurts, S. M. E., Ramaekers, B. L. T., Erdkamp, F., Vriens, B. E. P. J., Aaldering, K. N. A., van de Wouw, A. J., Dercksen, M. W., Smilde, T. J., Peters, N. A. J. B., Riel, J. M. V., Pepels, M. J., Heijnen-Mommers, J., Joore, M. A., Tjan-Heijnen, V. C. G., & de Boer, M. (2020). The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry. Acta Oncologica, 59(1), 82-89. https://doi.org/10.1080/0284186X.2019.1670356

@article{bc5a76dcd7974ebfb812afd46c93754e,

title = "The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry",

abstract = "Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013-2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7-5.5) in the eribulin group and 3.2 months (95% CI: 2.0-4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49-1.38). Median OS was 5.9 months (95% CI: 4.6-11.0) and 5.2 months (95% CI: 4.6-9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38-1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.",

keywords = "Eribulin, breast neoplasms, matching, genetic matching, relative effectiveness, EXPANDED ACCESS PROGRAM, EFFICACY, MESYLATE, SAFETY, CAPECITABINE, MONOTHERAPY, MULTICENTER, TOXICITY",

author = "Pouwels, {X. G. L. V.} and Geurts, {S. M. E.} and Ramaekers, {B. L. T.} and F. Erdkamp and Vriens, {B. E. P. J.} and Aaldering, {K. N. A.} and {van de Wouw}, {A. J.} and Dercksen, {M. W.} and Smilde, {T. J.} and Peters, {N. A. J. B.} and Riel, {J. M. van} and Pepels, {M. J.} and J. Heijnen-Mommers and Joore, {M. A.} and Tjan-Heijnen, {V. C. G.} and {de Boer}, M.",

year = "2020",

month = jan,

day = "2",

doi = "10.1080/0284186X.2019.1670356",

language = "English",

volume = "59",

pages = "82--89",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Routledge/Taylor & Francis Group",

number = "1",

}

Pouwels, XGLV, Geurts, SME , Ramaekers, BLT, Erdkamp, F, Vriens, BEPJ, Aaldering, KNA, van de Wouw, AJ, Dercksen, MW, Smilde, TJ, Peters, NAJB, Riel, JMV, Pepels, MJ, Heijnen-Mommers, J, Joore, MA , Tjan-Heijnen, VCG & de Boer, M 2020, 'The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry', Acta Oncologica, vol. 59, no. 1, pp. 82-89. https://doi.org/10.1080/0284186X.2019.1670356

TY - JOUR

T1 - The relative effectiveness of eribulin for advanced breast cancer treatment

T2 - a study of the southeast Netherlands advanced breast cancer registry

AU - Pouwels, X. G. L. V.

AU - Geurts, S. M. E.

AU - Ramaekers, B. L. T.

AU - Erdkamp, F.

AU - Vriens, B. E. P. J.

AU - Aaldering, K. N. A.

AU - van de Wouw, A. J.

AU - Dercksen, M. W.

AU - Smilde, T. J.

AU - Peters, N. A. J. B.

AU - Riel, J. M. van

AU - Pepels, M. J.

AU - Heijnen-Mommers, J.

AU - Joore, M. A.

AU - Tjan-Heijnen, V. C. G.

AU - de Boer, M.

PY - 2020/1/2

Y1 - 2020/1/2

N2 - Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013-2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7-5.5) in the eribulin group and 3.2 months (95% CI: 2.0-4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49-1.38). Median OS was 5.9 months (95% CI: 4.6-11.0) and 5.2 months (95% CI: 4.6-9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38-1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.

AB - Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013-2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7-5.5) in the eribulin group and 3.2 months (95% CI: 2.0-4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49-1.38). Median OS was 5.9 months (95% CI: 4.6-11.0) and 5.2 months (95% CI: 4.6-9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38-1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.

KW - Eribulin

KW - breast neoplasms

KW - matching

KW - genetic matching

KW - relative effectiveness

KW - EXPANDED ACCESS PROGRAM

KW - EFFICACY

KW - MESYLATE

KW - SAFETY

KW - CAPECITABINE

KW - MONOTHERAPY

KW - MULTICENTER

KW - TOXICITY

U2 - 10.1080/0284186X.2019.1670356

DO - 10.1080/0284186X.2019.1670356

M3 - Article

C2 - 31583931

VL - 59

SP - 82

EP - 89

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 1

ER -